Now showing items 1-20 of 20

    • 3D modelling identifies novel genetic dependencies associated with breast cancer progression in the isogenic MCF10 model. 

      Maguire, SL; Peck, B; Wai, PT; Campbell, J; Barker, H; Gulati, A; Daley, F; Vyse, S; Huang, P; Lord, CJ; Farnie, G; Brennan, K; Natrajan, R (2016-08-11)
      The initiation and progression of breast cancer from the transformation of the normal epithelium to ductal carcinoma in situ (DCIS) and invasive disease is a complex process involving the acquisition of genetic alterations, ...
    • Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast. 

      Natrajan, R; Wilkerson, PM; Marchiò, C; Piscuoglio, S; Ng, CK; Wai, P; Lambros, MB; Samartzis, EP; Dedes, KJ; Frankum, J; Bajrami, I; Kopec, A; Mackay, A; A'hern, R; Fenwick, K; Kozarewa, I; Hakas, J; Mitsopoulos, C; Hardisson, D; Lord, CJ; Kumar-Sinha, C; Ashworth, A; Weigelt, B; Sapino, A; Chinnaiyan, AM; Maher, CA; Reis-Filho, JS (2014-04)
      Micropapillary carcinoma (MPC) is a rare histological special type of breast cancer, characterized by an aggressive clinical behaviour and a pattern of copy number aberrations (CNAs) distinct from that of grade- and oestrogen ...
    • Comparative proteomic assessment of matrisome enrichment methodologies. 

      Krasny, L; Paul, A; Wai, P; Howard, BA; Natrajan, RC; Huang, PH (2016-09-02)
      The matrisome is a complex and heterogeneous collection of extracellular matrix (ECM) and ECM-associated proteins that play important roles in tissue development and homeostasis. While several strategies for matrisome ...
    • Driver Oncogenes but Not as We Know Them: Targetable Fusion Genes in Breast Cancer. 

      Natrajan, R; Tutt, ANJ; Lord, CJ (2018-03)
      <b/> Two reports in this issue of Cancer Discovery outline how the genomic composition of tumors, including the presence of intragenic gene fusions, could inform the selection of treatment approaches in aggressive forms ...
    • Dual Targeting of PDGFRα and FGFR1 Displays Synergistic Efficacy in Malignant Rhabdoid Tumors. 

      Wong, JP; Todd, JR; Finetti, MA; McCarthy, F; Broncel, M; Vyse, S; Luczynski, MT; Crosier, S; Ryall, KA; Holmes, K; Payne, LS; Daley, F; Wai, P; Jenks, A; Tanos, B; Tan, A-C; Natrajan, RC; Williamson, D; Huang, PH (2016-10-25)
      Subunits of the SWI/SNF chromatin remodeling complex are mutated in a significant proportion of human cancers. Malignant rhabdoid tumors (MRTs) are lethal pediatric cancers characterized by a deficiency in the SWI/SNF ...
    • E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer. 

      Bajrami, I; Marlow, R; van de Ven, M; Brough, R; Pemberton, HN; Frankum, J; Song, F; Rafiq, R; Konde, A; Krastev, DB; Menon, M; Campbell, J; Gulati, A; Kumar, R; Pettitt, SJ; Gurden, MD; Cardenosa, ML; Chong, I; Gazinska, P; Wallberg, F; Sawyer, EJ; Martin, L-A; Dowsett, M; Linardopoulos, S; Natrajan, R; Ryan, CJ; Derksen, PWB; Jonkers, J; Tutt, ANJ; Ashworth, A; Lord, CJ (2018-04)
      The cell adhesion glycoprotein E-cadherin (CDH1) is commonly inactivated in breast tumors. Precision medicine approaches that exploit this characteristic are not available. Using perturbation screens in breast tumor cells ...
    • Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response-Targeted Therapies in Breast Cancer. 

      Naidoo, K; Wai, PT; Maguire, SL; Daley, F; Haider, S; Kriplani, D; Campbell, J; Mirza, H; Grigoriadis, A; Tutt, A; Moseley, PM; Abdel-Fatah, TMA; Chan, SYT; Madhusudan, S; Rhaka, EA; Ellis, IO; Lord, CJ; Yuan, Y; Green, AR; Natrajan, R (2018-01)
      Disruption of Cyclin-Dependent Kinase 12 (CDK12) is known to lead to defects in DNA repair and sensitivity to platinum salts and PARP1/2 inhibitors. However, CDK12 has also been proposed as an oncogene in breast cancer. ...
    • From integrative genomics to therapeutic targets. 

      Natrajan, R; Wilkerson, P (2013-06-05)
      Combinatorial approaches that integrate conventional pathology with genomic profiling and functional genomics have begun to enhance our understanding of the genetic basis of breast cancer. These methods have identified key ...
    • Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines. 

      Campbell, J; Ryan, CJ; Brough, R; Bajrami, I; Pemberton, HN; Chong, IY; Costa-Cabral, S; Frankum, J; Gulati, A; Holme, H; Miller, R; Postel-Vinay, S; Rafiq, R; Wei, W; Williamson, CT; Quigley, DA; Tym, J; Al-Lazikani, B; Fenton, T; Natrajan, R; Strauss, SJ; Ashworth, A; Lord, CJ (2016-03-02)
      One approach to identifying cancer-specific vulnerabilities and therapeutic targets is to profile genetic dependencies in cancer cell lines. Here, we describe data from a series of siRNA screens that identify the kinase ...
    • Multifaceted dysregulation of the epidermal growth factor receptor pathway in clear cell sarcoma of the kidney. 

      Little, SE; Bax, DA; Rodriguez-Pinilla, M; Natrajan, R; Messahel, B; Pritchard-Jones, K; Vujanic, GM; Reis-Filho, JS; Jones, C (2007-08)
      PURPOSE: Epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase overexpressed in a variety of human malignancies, against which targeted therapies have shown efficacy in lung and brain tumors. Clinical ...
    • Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers. 

      Khalique, S; Naidoo, K; Attygalle, AD; Kriplani, D; Daley, F; Lowe, A; Campbell, J; Jones, T; Hubank, M; Fenwick, K; Matthews, N; Rust, AG; Lord, CJ; Banerjee, S; Natrajan, R (2018-07)
      ARID1A is a tumour suppressor gene that is frequently mutated in clear cell and endometrioid carcinomas of the ovary and endometrium and is an important clinical biomarker for novel treatment approaches for patients with ...
    • Preclinical evaluation of the PARP inhibitor BMN-673 for the treatment of ovarian clear cell cancer. 

      Wilkerson, PM; Dedes, KJ; Samartzis, EP; Dedes, I; Lambros, MB; Natrajan, R; Gauthier, A; Piscuoglio, S; Töpfer, C; Vukovic, V; Daley, F; Weigelt, B; Reis-Filho, JS (2017-01-24)
      PURPOSE: To determine if models of ovarian clear cell carcinomas (OCCCs) harbouring defects in homologous recombination (HR) DNA repair of double strand breaks (DSBs) are sensitive to cisplatin and/or PARP inhibition. ...
    • The spatio-temporal evolution of lymph node spread in early breast cancer 

      Barry, P; Vatsiou, A; Spiteri Sagastume, I; Nichol, D; Cresswell, G; Acar, A; Trahearn, N; Hrebien, S; Garcia-Murillas, I; Chkhaidze, K; Ermini, L; Cottom, H; Zabaglo, L; Koelble, K; Khalique, S; Rusby, J; Muscara, F; Dowsett, M; Maley, C; Natrajan, R; Yuan, Y; Schiavon, G; Turner, N; Sottoriva, A
    • The Spatiotemporal Evolution of Lymph Node Spread in Early Breast Cancer. 

      Barry, P; Vatsiou, A; Spiteri, I; Nichol, D; Cresswell, GD; Acar, A; Trahearn, N; Hrebien, S; Garcia-Murillas, I; Chkhaidze, K; Ermini, L; Huntingford, IS; Cottom, H; Zabaglo, L; Koelble, K; Khalique, S; Rusby, JE; Muscara, F; Dowsett, M; Maley, CC; Natrajan, R; Yuan, Y; Schiavon, G; Turner, N; Sottoriva, A (2018-10-01)
      Purpose: The most significant prognostic factor in early breast cancer is lymph node involvement. This stage between localized and systemic disease is key to understanding breast cancer progression; however, our knowledge ...
    • Splicing dysregulation as a driver of breast cancer. 

      Read, A; Natrajan, R (2018-09)
      Breast cancer is known to be a heterogeneous disease driven by a large repertoire of molecular abnormalities, which contribute to its diverse clinical behaviour. Despite the success of targeted therapy approaches for breast ...
    • SWATH mass spectrometry as a tool for quantitative profiling of the matrisome. 

      Krasny, L; Bland, P; Kogata, N; Wai, P; Howard, BA; Natrajan, RC; Huang, PH (2018-10-30)
      Proteomic analysis of extracellular matrix (ECM) and ECM-associated proteins, collectively known as the matrisome, is a challenging task due to the inherent complexity and insolubility of these proteins. Here we present ...
    • Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib. 

      Miller, RE; Brough, R; Bajrami, I; Williamson, CT; McDade, S; Campbell, J; Kigozi, A; Rafiq, R; Pemberton, H; Natrajan, R; Joel, J; Astley, H; Mahoney, C; Moore, JD; Torrance, C; Gordan, JD; Webber, JT; Levin, RS; Shokat, KM; Bandyopadhyay, S; Lord, CJ; Ashworth, A (2016-07)
      New targeted approaches to ovarian clear cell carcinomas (OCCC) are needed, given the limited treatment options in this disease and the poor response to standard chemotherapy. Using a series of high-throughput cell-based ...
    • Systematic analysis of tumour cell-extracellular matrix adhesion identifies independent prognostic factors in breast cancer. 

      Todd, JR; Ryall, KA; Vyse, S; Wong, JP; Natrajan, RC; Yuan, Y; Tan, AC; Huang, PH (2016-08-17)
      Tumour cell-extracellular matrix (ECM) interactions are fundamental for discrete steps in breast cancer progression. In particular, cancer cell adhesion to ECM proteins present in the microenvironment is critical for ...
    • Transcriptomic analysis of tubular carcinomas of the breast reveals similarities and differences with molecular subtype-matched ductal and lobular carcinomas. 

      Lopez-Garcia, MA; Geyer, FC; Natrajan, R; Kreike, B; Mackay, A; Grigoriadis, A; Reis-Filho, JS; Weigelt, B (2010-09)
      Tubular carcinoma (TC) is an uncommon special type of breast cancer characterized by an indolent clinical course. Although described as part of a spectrum of related lesions named 'low-grade breast neoplasia family' due ...
    • Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures. 

      Morrison, E; Wai, P; Leonidou, A; Bland, P; Khalique, S; Farnie, G; Daley, F; Peck, B; Natrajan, R (2016-12-26)
      The identification of functional driver events in cancer is central to furthering our understanding of cancer biology and indispensable for the discovery of the next generation of novel drug targets. It is becoming apparent ...